
Opinion|Videos|July 9, 2024
Role of the Pharmacist in Vaccinating Against RSV
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
Carrie Koenigsfeld, PharmD, FAPhA, shares strategies that pharmacists can use to effectively tackle vaccine hesitancy, particularly concerning newer vaccines such as the RSV vaccine, through building trust with patients to encourage informed decision-making.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What strategies can a pharmacist employ to effectively address vaccine hesitancy, especially with newer vaccines?
- What additional information on this subject do you feel your peers or colleagues would benefit from knowing?
Advertisement
Related to this article

Peptide cancer vaccines target neoantigens to boost T cells, with promising melanoma and pancreatic trials hinting at a new era in immunotherapy.

AI tools in pharmacy education risk eroding critical thinking, lab competency, and patient safety if used as substitutes for foundational learning.

The Main Street Pharmacy Access Act would let Medicare pay pharmacists for care they can already legally provide, if pharmacies have the time.

Ali A. Habib, MD, discusses how NIMBLE’s hospitalization findings complement symptom outcomes for investigational cemdisiran and highlights pharmacists’ role in vaccination tracking and infection-risk counseling.

Rather than requiring a new trial, the FDA extended evidence from carcinoma in situ to high-grade papillary-only disease, a new approach for this setting.

Pharmacists can address patient fears about fentanyl by distinguishing illicit from prescribed opioids and promoting safe, empathetic, evidence-based opioid use.
Advertisement
Advertisement
Trending on Pharmacy Times
1
VYD2311 May Offer Vaccine-Hesitant and Immunocompromised Individuals a New COVID-19 Immunization Option
2
National Pharmacy Technician Day: Celebrating the Backbone of Pharmacy
3
Pneumonic Plague: What Pharmacists Need to Know About Treatment
4
Cemdisiran’s Potential to Reduce Hospitalizations in Myasthenia Gravis
5



